Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brexpiprazole - Lundbeck/Otsuka

Drug Profile

Brexpiprazole - Lundbeck/Otsuka

Alternative Names: Lu-AF41156; OPC-34712; OPDC-34712; Rexulti; Rxulti

Latest Information Update: 14 May 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Developer Lundbeck A/S; Otsuka Beijing Research Institute; Otsuka Pharmaceutical Development & Commercialization; University of Chicago
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Piperazines; Quinolines; Sleep disorder therapies; Small molecules; Thiophenes
  • Mechanism of Action Dopamine D2 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder; Schizophrenia
  • Phase III Agitation; Bipolar disorders; Post-traumatic stress disorders; Sleep disorders
  • Phase II Borderline personality disorders
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 14 Aug 2019 Lundbeck and Otsuka plan a pivotal phase III trial for Post-traumatic stress disorders (Combination therapy) in Q4 2019
  • 14 Aug 2019 Lundbeck and Otsuka plan a proof-of-concept trial for Borderline personality disorders in Q4 2019
  • 05 May 2019 Phase-III clinical trials in Schizophrenia in China (PO) (NCT03874494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top